Molecular liaisons between erythropoiesis and iron metabolism

Blood

Volumn 124, Issue 4, 2014, Pages 479-482

  Kautz, Leon ^a   Nemeth, Elizabeta ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROFERRONE; HEPCIDIN; IRON; UNCLASSIFIED DRUG;

ARTICLE; ERYTHROPOIESIS; HUMAN; IRON METABOLISM; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; ERYTHROPOIESIS; HEPCIDINS; HUMANS; IRON;

EID: 84904865496     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-516252     Document Type: Article

References (34)

1. Ponka P, Sheftel AD. Erythroid iron metabolism. In: Anderson GJ, McLaren GD, eds. Iron Physiology and Pathophysiology in Humans. New York, NY: Humana Press; 2012:191-209.
2. Finch C. Regulators of iron balance in humans. Blood. 1994;84(6):1697-1702. (Pubitemid 24286117)
3. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62:347-360.
4. Qiao B, Sugianto P, Fung E, et al. Hepcidininduced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 2012; 15(6):918-924.
5. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in betathalassemia. Haematologica. 2007;92(5): 583-588. (Pubitemid 350144260)
6. Pasricha SR, Frazer DM, Bowden DK, Anderson GJ. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with b-thalassemia major: a longitudinal study. Blood. 2013;122(1):124-133.
7. Centis F, Tabellini L, Lucarelli G, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood. 2000;96(10):3624-3629.
8. Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in b-thalassemic mice. J Clin Invest. 2010;120(12):4466-4477.
9. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108(12): 3730-3735. (Pubitemid 44864551)
10. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006;55(6): 667-674. (Pubitemid 46021227)
11. Mastrogiannaki M, Matak P, Mathieu JR, et al. Hepatic hypoxia-inducible factor-2 downregulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica. 2012;97(6): 827-834.
12. Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest. 2012;122(12):4635-4644.
13. Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010;95(3):505-508.
14. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096-1101. (Pubitemid 47517510)
15. Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009;114(1): 181-186.
16. Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 2013; 24(4):373-384.
17. Forsman CL, Ng BC, Heinze RK, et al. BMP-binding protein twisted gastrulation is required in mammary gland epithelium for normal ductal elongation and myoepithelial compartmentalization. Dev Biol. 2013;373(1): 95-106.
18. Frazer DM, Wilkins SJ, Darshan D, Badrick AC, McLaren GD, Anderson GJ. Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression. Br J Haematol. 2012;157(5):615-626.
19. Casanovas G, Vujić Spasic M, Casu C, et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica. 2013;98(3): 444-447.
20. Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood. 2008; 112(13):5241-5244.
21. An X, Schulz VP, Li J, et al. Global transcriptome analyses of human and murine terminal erythroid differentiation. Blood. 2014;123(22):3466-3477.
22. Talbot NP, Lakhal S, Smith TG, et al. Regulation of hepcidin expression at high altitude. Blood. 2012;119(3):857-860.
23. Robach P, Recalcati S, Girelli D, et al. Serum hepcidin levels and muscle iron proteins in humans injected with low- or high-dose erythropoietin. Eur J Haematol. 2013;91(1):74-84.
24. Tanno T, Rabel A, Lee YT, Yau YY, Leitman SF, Miller JL. Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. Transfusion. 2010;50(7):1532-1535.
25. Theurl I, Finkenstedt A, Schroll A, et al. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol. 2010;148(3):449-455.
26. Waalen J, von Löhneysen K, Lee P, Xu X, Friedman JS. Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause. Eur J Haematol. 2011;87(2): 107-116.
27. Lakhal S, Talbot NP, Crosby A, et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood. 2009;113(7):1555-1563.
28. Santini V, Girelli D, Sanna A, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS ONE. 2011; 6(8):e23109.
29. Tarkun P, Mehtap O, Atesoǧlu EB, Geduk A, Musul MM, Hacihanefioglu A. Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. Eur J Haematol. 2013;91(3): 228-235.
30. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism [published online ahead of print June 1, 2014]. Nat Genet.
31. Porpiglia E, Hidalgo D, Koulnis M, Tzafriri AR, Socolovsky M. Stat5 signaling specifies basal versus stress erythropoietic responses through distinct binary and graded dynamic modalities. PLoS Biol. 2012;10(8):e1001383.
32. Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014;35(3):155-161.
33. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4): 408-414.
34. Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in b-thalassemia. Nat Med. 2014; 20(4):398-407.